Preoperative chemoradiation with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma

Alonso, Vicente; Salud, Antonieta; Escudero, P.; Valencia, Javier; Mira, M.; Lobera, A. Ruiz de; Lambea, J.; Grandez, R.; Trés, A.; Antón, A.

doi:10.1200/jco.2004.22.90140.3607

Search citation statements

Order By: Relevance

Paper Sections

Select...

Other1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2008

2010

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several phase I/II trials have examined oxaliplatin plus a fluoropyrimidine as radiation sensitizers in rectal cancer CRT [89–101] (Table 2). Response rates in terms of pCR appear to be increased compared with historical reports using a single agent fluoropyrimidine.…”

Section: Increasing the Potency Of Chemoradiation Regimes: Potential mentioning

confidence: 99%

Radiation, chemotherapy and biological therapy in the curative treatment of locally advanced rectal cancer

Gollins

2010

Colorectal Disease

View full text Add to dashboard Cite

show abstract

Section: Increasing the Potency Of Chemoradiation Regimes: Potential mentioning

confidence: 99%

Radiation, chemotherapy and biological therapy in the curative treatment of locally advanced rectal cancer

Gollins

2010

Colorectal Disease

View full text Add to dashboard Cite

show abstract

Irinotecan+5-fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: a phase I/II study

et al. 2008

View full text Add to dashboard Cite

In the UK, 10% of patients diagnosed with rectal cancer have inoperable disease at presentation. This study ascertained whether the resectability rate of inoperable locally advanced rectal cancer was improved by administration of intravenous irinotecan, 5-fluorouracil (5-FU) and pelvic radiotherapy. During phase I of the trial (n ¼ 12), the dose of irinotecan was escalated in three-patient cohorts from 50 mg m À2 to 60 mg m À2 to 70 mg m À2 to identify the maximum tolerated dose (60 mg m À2 ). In phase II, 31 patients with nonresectable disease received 45 Gy radiotherapy and 5-FU infusions (200 mg m À2 per day) for 5 weeks. Irinotecan (60 mg m À2 ) was given on days 1, 8, 15 and 22. After treatment, patients were operated on if possible. Thirty patients completed the protocol, 28 underwent surgery. Before surgery, MRI restaging of 24 patients showed that 19 (79%) had a reduction in tumour stage after treatment (seven complete clinical response and 12 partial). Of 27 patients followed up after surgery, 22 (81%) had clear circumferential resection margins. Disease-free and overall survival estimates at 3 years were 65 and 90%, respectively. The regimen was well tolerated. Irinotecan, 5-FU and radiotherapy results in tumour downgrading, allowing resection of previously inoperable tumour with acceptable toxicity.

show abstract

Preoperative chemoradiation with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma

Cited by 2 publications

References 0 publications

Radiation, chemotherapy and biological therapy in the curative treatment of locally advanced rectal cancer

Radiation, chemotherapy and biological therapy in the curative treatment of locally advanced rectal cancer

Irinotecan+5-fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: a phase I/II study

Contact Info

Product

Resources

About